10-QPeriod: Q2 FY2024

Edwards Lifesciences Corp Quarterly Report for Q2 Ended Jun 30, 2024

Filed July 31, 2024For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) reported solid financial results for the second quarter and the first six months of 2024, demonstrating continued growth in its core structural heart disease business. Net sales increased by 7.0% year-over-year for the quarter and 7.9% for the first six months, primarily driven by strong performance in Transcatheter Aortic Valve Replacement (TAVR) and significant growth in Transcatheter Mitral and Tricuspid Therapies (TMTT). The company is strategically divesting its Critical Care product group, having entered into a definitive agreement for its sale in June 2024. This move is expected to sharpen focus on core growth areas and allow for reinvestment in interventional heart failure technologies. While the sale is pending regulatory approval, the financial results reflect Critical Care as discontinued operations. Despite some headwinds, including lower-than-expected TAVR growth in the US and currency fluctuations impacting gross margins, the company maintains a positive outlook, supported by ongoing investments in R&D and strategic acquisitions. Key financial highlights include continued revenue growth, robust operating income, and effective management of operating expenses. The company also provided updates on its ongoing tax litigations, which remain a significant contingency but are being actively managed. Overall, the report indicates a company strategically positioning itself for future growth while navigating competitive and regulatory landscapes.

Financial Highlights

50 data points
Beta

Revenue

$1.37B

79.9% Gross Margin

Net Income

$365.00M

26.7% Net Margin

EPS (Diluted)

$0.61

Total Assets

$10.10B

Cash & Equivalents

$1.66B

Free Cash Flow

$286.10M

Financial Statements
Beta
Revenue$1.37B
Cost of Revenue$275.50M
Gross Profit$1.09B
R&D Expenses$271.80M
SG&A Expenses$447.50M
Operating Income$366.50M
Net Income$365.00M
EPS (Basic)$0.61
EPS (Diluted)$0.61
Shares Outstanding (Basic)602.10M
Shares Outstanding (Diluted)604.30M

Key Highlights

  • 1Net sales increased by 7.0% to $1.39 billion for the three months ended June 30, 2024, and by 7.9% to $2.73 billion for the six months ended June 30, 2024, driven by strong performance in TAVR and TMTT.
  • 2The company announced a definitive agreement to sell its Critical Care product group for $4.2 billion, which is expected to close by the end of Q3 2024. The results of this segment are presented as discontinued operations.
  • 3Transcatheter Mitral and Tricuspid Therapies (TMTT) sales saw significant growth of 74.7% for the quarter and 74.9% for the six months, largely due to the PASCAL system and the launch of the EVOQUE tricuspid valve replacement system.
  • 4Operating income for the quarter increased by 36.7% to $369.1 million, and for the six months by 19.8% to $720.2 million, reflecting strong sales growth and management of expenses.
  • 5The company repurchased 1.7 million shares for $150.0 million during the first six months of 2024, with $898.5 million remaining authorization for future share repurchases.
  • 6R&D expenses increased in the period, reflecting continued investment in aortic transcatheter valve innovations and clinical trials.
  • 7The company has substantial ongoing tax litigations, particularly concerning transfer pricing for Surgical/TAVR intercompany royalty transactions, with potential material impacts on financial statements.

Frequently Asked Questions

The Critical Care product group has been classified as discontinued operations in the financial statements. The agreement to sell this segment for $4.2 billion was entered into on June 3, 2024. The sale is expected to close by the end of the third quarter of 2024, subject to customary closing conditions and regulatory approvals. The company expects this divestiture to allow for a sharper focus on its core structural heart disease business and reinvestment in interventional heart failure technologies.

Net sales for Transcatheter Aortic Valve Replacement (TAVR) increased by 4.7% to $1.04 billion for the quarter and 5.5% to $2.05 billion for the six months, driven by the SAPIEN platform. However, the company noted lower-than-expected TAVR growth in the US due to regional competitive pressures and a reduction in procedures at certain hospitals. Transcatheter Mitral and Tricuspid Therapies (TMTT) showed exceptional growth, with sales up 74.7% to $83.0 million for the quarter and 74.9% to $155.9 million for the six months, boosted by the PASCAL system and the launch of the EVOQUE tricuspid valve replacement system.

Edwards Lifesciences faces several significant contingencies, most notably ongoing tax litigations. This includes a Notice of Deficiency from the IRS related to transfer pricing for Surgical/TAVR intercompany royalty transactions for tax years 2015-2017, with a potential additional tax liability of $269.3 million before interest and tax offsets. The company is contesting this through the judicial process and has made significant deposits to mitigate interest. Similar disputes may arise for later tax years. Additionally, the company received a notice of assessment from the Israel Tax Authority for approximately $110 million related to a claimed 2017 transfer of intellectual property. The company is also subject to other legal proceedings and investigations that could have a material impact if resolved unfavorably.

The company ended the quarter with strong liquidity, with cash and cash equivalents of $1.64 billion. Net cash provided by operating activities was $318.0 million for the first six months of 2024, though this was impacted by a $305.1 million tax deposit made to mitigate interest on contested tax liabilities. The company has a $750 million revolving credit facility with no outstanding balance as of June 30, 2024. Share repurchases continue, with $150.0 million spent in the first half of 2024 and $898.5 million remaining under authorization. Significant upcoming cash outlays are planned for strategic acquisitions totaling $1.5 billion announced in July 2024.